Aclaris Therapeutics Statistics
Total Valuation
ACRS has a market cap or net worth of $254.58 million. The enterprise value is $80.39 million.
Important Dates
The next estimated earnings date is Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ACRS has 108.33 million shares outstanding. The number of shares has increased by 44.96% in one year.
| Current Share Class | 108.33M |
| Shares Outstanding | 108.33M |
| Shares Change (YoY) | +44.96% |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | 2.69% |
| Owned by Institutions (%) | 56.19% |
| Float | 72.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.66 |
| Forward PS | 40.86 |
| PB Ratio | 1.97 |
| P/TBV Ratio | 1.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.88, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.88 |
| Quick Ratio | 3.73 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -101.41% and return on invested capital (ROIC) is -26.98%.
| Return on Equity (ROE) | -101.41% |
| Return on Assets (ROA) | -20.86% |
| Return on Invested Capital (ROIC) | -26.98% |
| Return on Capital Employed (ROCE) | -36.00% |
| Revenue Per Employee | $262,328 |
| Profits Per Employee | -$2.10M |
| Employee Count | 64 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +45.34% in the last 52 weeks. The beta is 0.28, so ACRS's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | +45.34% |
| 50-Day Moving Average | 1.97 |
| 200-Day Moving Average | 1.74 |
| Relative Strength Index (RSI) | 61.65 |
| Average Volume (20 Days) | 1,235,577 |
Short Selling Information
The latest short interest is 4.69 million, so 4.33% of the outstanding shares have been sold short.
| Short Interest | 4.69M |
| Short Previous Month | 5.55M |
| Short % of Shares Out | 4.33% |
| Short % of Float | 6.46% |
| Short Ratio (days to cover) | 4.48 |
Income Statement
In the last 12 months, ACRS had revenue of $16.79 million and -$134.65 million in losses. Loss per share was -$1.31.
| Revenue | 16.79M |
| Gross Profit | -36.30M |
| Operating Income | -58.43M |
| Pretax Income | -134.65M |
| Net Income | -134.65M |
| EBITDA | -58.26M |
| EBIT | -58.43M |
| Loss Per Share | -$1.31 |
Full Income StatementBalance Sheet
The company has $99.81 million in cash and $2.37 million in debt, giving a net cash position of $178.52 million or $1.65 per share.
| Cash & Cash Equivalents | 99.81M |
| Total Debt | 2.37M |
| Net Cash | 178.52M |
| Net Cash Per Share | $1.65 |
| Equity (Book Value) | 131.74M |
| Book Value Per Share | 1.22 |
| Working Capital | 77.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$9.99 million and capital expenditures -$64,000, giving a free cash flow of -$10.05 million.
| Operating Cash Flow | -9.99M |
| Capital Expenditures | -64,000 |
| Free Cash Flow | -10.05M |
| FCF Per Share | -$0.09 |
Full Cash Flow StatementMargins
| Gross Margin | -216.22% |
| Operating Margin | -348.04% |
| Pretax Margin | -802.03% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ACRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -44.96% |
| Shareholder Yield | -44.96% |
| Earnings Yield | -52.01% |
| FCF Yield | -3.88% |
Analyst Forecast
The average price target for ACRS is $9.25, which is 293.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.25 |
| Price Target Difference | 293.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 14.50% |
| EPS Growth Forecast (5Y) | -15.67% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ACRS has an Altman Z-Score of -5.54 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.54 |
| Piotroski F-Score | 1 |
